Rationale: Small 225Ac-labeled prostate-specific membrane antigen (PSMA)-targeted radioconjugates have been described for targeted alpha therapy of metastatic castration-resistant prostate cancer. Transient binding to serum albumin as a highly abundant, inherent transport protein represents a commonly applied strategy to modulate the tissue distribution profile of such low-molecular-weight radiotherapeutics and to enhance radioactivity uptake into tumor lesions with the ultimate objective of improved therapeutic outcome. Methods: Two ligands mcp-M-alb-PSMA and mcp-D-alb-PSMA were synthesized by combining a macropa-derived chelator with either one or two lysine-ureido-glutamate-based PSMA- and 4-(p-iodophenyl)butyrate albumin-binding entities using multistep peptide-coupling chemistry. Both compounds were labeled with [225Ac]Ac3+ under mild conditions and their reversible binding to serum albumin was analyzed by an ultrafiltration assay as well as microscale thermophoresis measurements. Saturation binding studies and clonogenic survival assays using PSMA-expressing LNCaP cells were performed to evaluate PSMA-mediated cell binding and to assess the cytotoxic potency of the novel radioconjugates [225Ac]Ac-mcp-M-alb-PSMA and [225Ac]Ac-mcp-D-alb-PSMA, respectively. Biodistributions of both 225Ac-radioconjugates were investigated using LNCaP tumor-bearing SCID mice. Histological examinations of selected organs were performed to analyze the occurrence of necrosis using H&E staining, DNA damage via γH2AX staining and proliferation via Ki67 expression in the tissue samples. Results: Enhanced binding to serum components in general and to human serum albumin in particular was revealed for [225Ac]Ac-mcp-M-alb-PSMA and [225Ac]Ac-mcp-D-alb-PSMA, respectively. Moreover, the novel derivatives are highly potent PSMA ligands as their KD values in the nanomolar range (23.38 and 11.56 nM) are comparable to the reference radioconjugates [225Ac]Ac-mcp-M-PSMA (30.83 nM) and [225Ac]Ac-mcp-D-PSMA (10.20 nM) without albumin binders. The clonogenic activity of LNCaP cells after treatment with the 225Ac-labeled ligands was affected in a dose- and time-dependent manner, whereas the bivalent radioconjugate [225Ac]Ac-mcp-D-alb-PSMA has a stronger impact on the clonogenic cell survival than its monovalent counterpart [225Ac]Ac-mcp-M-alb-PSMA. Biodistribution studies performed in LNCaP tumor xenografts showed prolonged blood circulation times for both albumin-binding radioconjugates and a substantially increased tumor uptake (46.04 ± 7.77 %ID/g for [225Ac]Ac-mcp-M-alb-PSMA at 128 h p.i. and 153.48 ± 37.76 %ID/g at 168 h p.i. for [225Ac]Ac-mcp-D-alb-PSMA) with favorable tumor-to-background ratios. Consequently, a clear histological indication of DNA damage was discovered in the tumor tissues, whereas DNA double-strand break formation in kidney and liver sections was less pronounced. Conclusion: The modification of the PSMA-based 225Ac-radioconjugates with one or two albumin-binding entities resulted in an improved radiopharmacological behavior including a greatly enhanced tumor accumulation combined with a rather low uptake in most non-targeted organs combined with a high excretion via the kidneys.

Helmholtz Zentrum Dresden Rossendorf Institute of Radiopharmaceutical Cancer Research Bautzner Landstraße 400 D‑01328 Dresden Germany

Palacky University Olomouc Faculty of Medicine and Dentistry Institute of Clinical and Molecular Pathology Hnevotinska 976 3 775 15 Olomouc Czech Republic

Palacky University Olomouc Faculty of Medicine and Dentistry Institute of Molecular and Translational Medicine and Czech Advanced Technology and Research Institute Hnevotinska 1333 5 779 00 Olomouc Czech Republic

Technische Universität Dresden Faculty of Chemistry and Food Chemistry D 01062 Dresden Germany

Zobrazit více v PubMed

Guerra Liberal FDC, O'Sullivan JM, McMahon SJ, Prise KM. Targeted alpha therapy: current clinical applications. Cancer Biother Radiopharm. 2020;35:404–17. PubMed

Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. α-Emitters for radiotherapy: from basic radiochemistry to clinical studies-part 1. J Nucl Med. 2018;59:878–84. PubMed PMC

Makvandi M, Dupis E, Engle JW, Nortier FM, Fassbender ME, Simon S. et al. Alpha-emitters and targeted alpha therapy in oncology: from basic science to clinical investigations. Target Oncol. 2018;13:189–203. PubMed

King AP, Lin FI, Escorcia FE. Why bother with alpha particles? Eur J Nucl Med Mol Imaging. 2021;49:7–17. PubMed

Roscher M, Bakos G, Benešová M. Atomic nanogenerators in targeted alpha therapies: Curie's legacy in modern cancer management. Pharmaceuticals. 2020;13:76. PubMed PMC

Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E. et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:824–45. PubMed

Gott M, Steinbach J, Mamat C. The radiochemical and radiopharmaceutical applications of radium. Open Chem. 2016;14:118–29.

Uccelli L, Martini P, Cittanti C, Carnevale A, Missiroli L, Giganti M. et al. Therapeutic radiometals: worldwide scientific literature trend analysis (2008-2018) Molecules. 2019;24:640. PubMed PMC

Nelson BJB, Andersson JD, Wuest F. Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications. Pharmaceutics. 2020;13:49. PubMed PMC

Eychenne R, Chérel M, Haddad F, Guérard F, Gestin JF. Overview of the most promising radionuclides for targeted alpha therapy: the "hopeful eight". Pharmaceutics. 2021;13:906. PubMed PMC

Hagemann UB, Ellingsen C, Schuhmacher J, Kristian A, Mobergslien A, Cruciani V. et al. Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers. Clin Cancer Res. 2019;25:4723–34. PubMed

Hagemann UB, Wickstroem K, Hammer S, Bjerke RM, Zitzmann-Kolbe S, Ryan OB. et al. Advances in precision oncology: targeted thorium-227 conjugates as a new modality in targeted alpha therapy. Cancer Biother Radiopharm. 2020;35:497–510. PubMed PMC

Bartoś B, Lyczko K, Kasperek A, Krajewski S, Bilewicz A. Search of ligands suitable for 212Pb/212Bi in vivo generators. J Radioanal Nucl Chem. 2013;295:205–9. PubMed PMC

Müller C, Vermeulen C, Köster U, Johnston K, Türler A, Schibli R. et al. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. EJNMMI Radiopharm Chem. 2017;1:5. PubMed PMC

Naskar N, Lahiri S. Theranostic terbium radioisotopes: challenges in production for clinical application. Front Med. 2021;8:675014. PubMed PMC

Müller C, Domnanich KA, Umbricht CA, van der Meulen NP. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application. Br J Radiol. 2018;91:1091. PubMed PMC

Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol. 2007;34:779–85. PubMed PMC

Zalutsky MR, Pruszynski M. Astatine-211: production and availability. Curr Radiopharm. 2011;4:177–85. PubMed PMC

Vaidyanathan G, Zalutsky MR. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. Curr Radiopharm. 2011;4:283–94. PubMed PMC

Choi J, Vaidyanathan G, Koumarianou E, Kang CM, Zalutsky MR. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation. Nucl Med Biol. 2018;56:10–20. PubMed PMC

Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with 225actinium and 213bismuth. Curr Radiopharm. 2018;11:200–8. PubMed PMC

Morgenstern A, Lilley LM, Stein BW, Kozimor SA, Batista ER, Yang P. Computer-assisted design of macrocyclic chelators for actinium-225 radiotherapeutics. Inorg Chem. 2021;60:623–32. PubMed

Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F. et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4. PubMed

Thiele NA, Brown V, Kelly JM, Amor-Coarasa A, Jermilova U, MacMillan SN. et al. An eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy. Angew Chem Int Ed Engl. 2017;56:14712–7. PubMed

Reissig F, Bauer D, Zarschler K, Novy Z, Bendova K, Ludik M-C. et al. Towards targeted alpha therapy with actinium-225: chelators for mild condition radiolabeling and targeting PSMA-a proof of concept study. Cancers (Basel) 2021;13:1974. PubMed PMC

Brandt M, Cardinale J, Giammei C, Guarrochena X, Happl B, Jouini N. et al. Mini-review: targeted radiopharmaceuticals incorporating reversible, low molecular weight albumin binders. Nucl Med Biol. 2019;70:46–52. PubMed

Lau J, Jacobson O, Niu G, Lin KS, Bénard F, Chen X. Bench to bedside: albumin binders for improved cancer radioligand therapies. Bioconjug Chem. 2019;30:487–502. PubMed

Dumelin CE, Trüssel S, Buller F, Trachsel E, Bootz F, Zhang Y. et al. A portable albumin binder from a DNA-encoded chemical library. Angew Chem Int Ed Engl. 2008;47:3196–201. PubMed

Deberle LM, Benešová M, Umbricht CA, Borgna F, Büchler M, Zhernosekov K. et al. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics. 2020;10:1678–93. PubMed PMC

Kuo H-T, Lin K-S, Zhang Z, Uribe CF, Merkens H, Zhang C. et al. 177Lu-labeled albumin-binder - conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio. J Nucl Med. 2021;62:521–7. PubMed PMC

Benešová M, Umbricht CA, Schibli R, Müller C. Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Mol Pharm. 2018;15:934–46. PubMed

Siwowska K, Haller S, Bortoli F, Benešová M, Groehn V, Bernhardt P. et al. Preclinical comparison of albumin-binding radiofolates: impact of linker entities on the in vitro and in vivo properties. Mol Pharm. 2017;14:523–32. PubMed

Umbricht CA, Benešová M, Schibli R, Müller C. Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Mol Pharm. 2018;15:2297–306. PubMed

Müller C, Struthers H, Winiger C, Zhernosekov K, Schibli R. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice. J Nucl Med. 2013;54:124–31. PubMed

Brandt F, Ullrich M, Laube M, Kopka K, Bachmann M, Löser R. et al. “Clickable” albumin binders for modulating the tumor uptake of targeted radiopharmaceuticals. J Med Chem. 2022;65:710–33. PubMed

Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C. et al. Enhancing treatment efficacy of 177Lu-PSMA-617 with the conjugation of an albumin-binding motif: preclinical dosimetry and endoradiotherapy studies. Mol Pharm. 2018;15:5183–91. PubMed

Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC. et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705. PubMed

Merlot AM, Kalinowski DS, Richardson DR. Unraveling the mysteries of serum albumin-more than just a serum protein. Front Physiol. 2014;5:299. PubMed PMC

Leboffe L, di Masi A, Polticelli F, Trezza V, Ascenzi P. Structural basis of drug recognition by human serum albumin. Curr Med Chem. 2020;27:4907–31. PubMed

Liu Y, Chen M, Bian G, Liu J, Song L. Spectroscopic investigation of the interaction of the toxicant, 2-naphthylamine, with bovine serum albumin. J Biochem Mol Toxicol. 2011;25:362–8. PubMed

Hulme EC, Trevethick MA. Ligand binding assays at equilibrium: validation and interpretation. Brit J Pharmacol. 2010;161:1219–37. PubMed PMC

Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W. et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of Prostate Cancer. J Nucl Med. 2015;56:914–20. PubMed

Fan X, Wang L, Guo Y, Tu Z, Li L, Tong H. et al. Ultrasonic nanobubbles carrying anti-PSMA nanobody: construction and application in prostate cancer-targeted imaging. PLoS One. 2015;10:e0127419. PubMed PMC

Schmid H-P, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 1993;71:2031–40. PubMed

Strohalm M, Kavan D, Novák P, Volný M, Havlícek V. mMass 3: a cross-platform software environment for precise analysis of mass spectrometric data. Anal Chem. 2010;82:4648–51. PubMed

Scheuermann T H, Padrick SB, Gardner KH, Brautigam CA. On the acquisition and analysis of microscale thermophoresis data. Anal Biochem. 2016;496:79–93. PubMed PMC

Dam JH, Olsen BB, Baun C, Høilund-Carlsen PF, Thisgaard H. A PSMA ligand labeled with cobalt-55 for PET imaging of prostate cancer. Mol Imaging Biol. 2017;19:915–22. PubMed

Kurfurstova D, Bartkova J, Vrtel R, Mickova A, Burdova A, Majera D. et al. DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer. Mol Oncol. 2016;10:879–94. PubMed PMC